Skip to main content

REVIEW article

Oncol. Rev.
Sec. Oncology Reviews: Reviews
Volume 18 - 2024 | doi: 10.3389/or.2024.1445826

Biomarker Testing in Lung Cancer : From bench to bedside

Provisionally accepted
Ullas Batra Ullas Batra 1*Shrinidhi Nathany Shrinidhi Nathany 2
  • 1 Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
  • 2 Fortis Memorial Research Institute, Gurgaon, Haryana, India

The final, formatted version of the article will be published soon.

    NSCLC is the poster child of personalized medicine. With the increased knowledge about biomarkers and consequent improved survival, NSCLC has changed from being a therapeutic nihilistic disease to that of therapeutic enthusiasm. The routine biomarkers tested in NSCLC are EGFR, ALK, ROS1. However, several additional biomarkers have been added to the diagnostic landscape. Current guidelines recommend testing at least 7 biomarkers upfront at the time of NSCLC diagnosis-emphasizing the wide breadth of targets and corresponding therapies that can be leveraged for disease management. Sequential single gene testing is not only time consuming, but leads to tissue exhaustion. Multigene panel testing using next-generation sequencing (NGS) offers an attractive diagnostic substitute that can keep pace with the dynamics of precision medicine. NGS enables identification of point mutations, insertions, deletions, copy number alterations, fusion genes, and microsatellite instability information needed to guide the potential use of targeted therapy. This article reviews the existing guidelines and proposed recommendations for NGS in non-squamous NSCLC, the real world data for the same and the utility of upfront broader panel based NGS testing over single gene testing.

    Keywords: biomarker, Next generation seqeuncing (NGS), targeted therapy, lung cancer, precision oncology

    Received: 08 Jun 2024; Accepted: 12 Dec 2024.

    Copyright: © 2024 Batra and Nathany. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ullas Batra, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.